Zanubrutinib in Previously Treated CLL/SLL, MCL, MZL, or WM Intolerant to Ibrutinib/Acalabrutinib

 SLIDE KIT   12   08/2021

This phase 2 study evaluates the safety of zanubrutinib (BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma patients who have become intolerant of prior ibrutinib and/or acalabrutinib treatment, by comparing intolerance to adverse event (AE) profile as assessed by the recurrence and the change in severity of adverse events.

Intolerable AEs experienced on ibrutinib or acalabrutinib were unlikely to recur with zanubrutinib, and zanubrutinib was tolerable (with 89% of patients remaining on zanubrutinib at time of data cutoff) and effective (patient’s disease was controlled or responded to therapy). These data suggest that zanubrutinib may provide a therapeutic option in patients intolerant to other BTK inhibitors across hematologic malignancies

Rating

Rate this resource